NCT05690646View on ClinicalTrials.gov

Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

491

Participants

Timeline

Start Date

January 28, 2023

Primary Completion Date

March 24, 2023

Study Completion Date

January 6, 2026

Conditions
Cardiac Surgery
Interventions
DRUG

Nirmatrelvir/ritonavir

nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days

DRUG

Ursodeoxycholic acid

ursodeoxycholic acid 15mg/kg/day bid for5 days

Trial Locations (1)

10010

Fuwai Hospital, Beijing

All Listed Sponsors
lead

China National Center for Cardiovascular Diseases

OTHER_GOV